The glutathione (GSH) synthesis inhibitor, buthionine sulfoximine (BSO) was tested for cytotoxicity and thiol depletion in murine and human tumor cells in vitro, and for its antitumor activity and toxicity in vivo. The cell lines used in these studies included murine L-1210 leukemia, human RPMI 8226
Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells
✍ Scribed by M. Joan Allalunis-Turner; Rufus S. Day; John D. S. McKean; Kenneth C. Petruk; Peter B. R. Allen; Keith E. Aronyk; Bryce K. A. Weir; Debbie Huyser-Wierenga; Dorcas S. Fulton; R. C. Urtasun
- Publisher
- Springer US
- Year
- 1991
- Tongue
- English
- Weight
- 796 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0167-594X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Glutathione (GSH) has often been implicated in the mechanism of resistance to platinum anti‐cancer drugs. It has been suggested that GSH may reduce the cytotoxicity of these drugs by forming inactive conjugates and by enhancing the repair of DNA‐platinum crosslinks. In the present study
## Abstract Bcl‐2 is a key antiapoptotic protein, and it confers survival advantages on many types of tumors by inhibiting apoptotic cell death. Malignant gliomas are the most common primary central nervous system tumors, but the role of bcl‐2 in these tumors has not been defined. We investigated t
## Abstract Glutathione‐__S__‐transferases (GSTs) are upregulated in malignant gliomas and contribute to their chemoresistance. The nitric oxide (NO) donor PABA/NO (O^2^‐{2,4‐dinitro‐5‐[4‐(__N__‐methylamino)benzoyloxy]phenyl} 1‐(__N__,__N__‐dimethylamino)diazen‐1‐ium‐1,2‐diolate) generates NO upon